Clinical Trial Update: Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP) [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 study of lenacapavir administered twice yearly for HIV pre-exposure prophylaxis; the trial is currently active but not recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Lenacapavir (lenacapavir)

Snippet

Sponsor: Gilead Sciences | Conditions: Pre-Exposure Prophylaxis of HIV Infection | Phase 2 | Status: ACTIVE_NOT_RECRUITING